People in the News

Aug 09, 2018

Hal Barron, Hans Bishop

Grail has appointed Hal Barron and Hans Bishop to its board. Barron is the CSO and president of R&D at GlaxoSmithKline. Prior to that, he served as president of R&D at Calico. He has also held management positions at Roche Pharmaceuticals and Genentech and is associate adjunct professor of epidemiology and biostatistics at the University of California, San Francisco. 

Bishop founded Juno Therapeutics in 2013 and was the firm's president and CEO until this past March when it was acquired by Celgene. He previously served as executive-in-residence at Warburg Pincus and is currently on the boards of Agilent Technologies and Celgene.

Aug 08, 2018

Colin Albert

Genomiqa announced today that it has appointed Colin Albert as its new CEO. Albert previously held the roles of commercial head and regional general manager of the Asia-Pacific region for Roche Foundation Medicine. Prior to those roles, he served as VP of business effectiveness and strategy at Shanghai Roche Pharmaceuticals.

Aug 07, 2018

David Macdonald

First Light Biosciences has appointed David Macdonald its president, CEO, and board member. He was most recently CEO of Agendia, and before that was a division president, COO and vice president at Quest Diagnostics. 

Aug 06, 2018

Mitchell Nelles

CareDx Chief Operating Officer Mitchell Nelles told the company on July 31 that he intends to retire, effective Sept. 28, according to a document filed with the US Securities Exchange Commission. Nelles joined CareDx in 2007, when it was called XDx, as VP of R&D. Prior to that, Nelles served as VP of North American R&D at BioMérieux.

Aug 02, 2018

Steve McPhail

Fluidigm Chief Operating Officer Steve McPhail will retire in early 2019, CEO Chris Linthwaite said on a conference call discussing Fluidigm's second quarter earnings. McPhail is retiring to focus on family and his involvement with Improve Care Now, a non-profit dedicated to improving quality of care for children with Crohn's disease and inflammatory bowel disease. McPhail serves on the board of directors for the non-profit, as well as the board of directors of the North Carolina Children's Hospital. He has served as COO at Fluidigm since August 2016. He also previously served as president and CEO of Expression Analysis.

Aug 02, 2018

Eric Stawiski

Eric Stawiski has been appointed vice president of bioinformatics at MedGenome. He is tasked with scaling up the company's bioinformatics services and building new products and IP. He was previously at Genentech where he was a group leader for a team focused on analyzing RNA-seq, exome, and copy number data to identify potential driver genes and drug targets in cancers, as well as evaluating new sequencing technologies. 

Aug 02, 2018

John Clarkson

Dubai-based genomics firm Agiomix has appointed John Clarkson as chairman. Clarkson was previously founder and commercial director of Molecular Sensing, a rapid DNA analysis company that was acquired by Osmetech (now GenMark Dx). Clarkson was also founding CEO of Atlas Genetics, and remains a non-executive director there.

Jul 31, 2018

Didier Hirsch, Robert McMahon, Karleen Oberton

Agilent Technologies said its senior VP and CFO Didier Hirsch will retire, effective Oct 31. The company has appointed Robert McMahon, currently CFO of Hologic, as his successor. McMahon will join Agilent on Aug. 3 as senior VP and will become CFO on Sept. 1 when Hirsch steps down from that post. Hirsch will continue as an active member of the executive staff until his retirement date at the end of the fiscal year and will work with McMahon to ensure a smooth transition.

Hirsch has served as Agilent's CFO since 2010. Before that, he had oversight of the corporate controllership and tax functions. He joined Agilent in 1999 as VP of treasury and investor relations. He also held various international finance positions at HP from 1989 until joining Agilent.
McMahon has served as Hologic's CFO since 2014. Prior to that, he spent 20 years with Johnson & Johnson, most recently as worldwide VP of finance and business development for Ortho Clinical Diagnostics. He also held a variety of financial leadership positions within Johnson & Johnson after joining the company in 1993.

Separately, Hologic said it would promote its current Chief Accounting Officer Karleen Oberton to replace McMahon as CFO. She joined Hologic in 2006 as corporate controller and was promoted to her current position in 2015. Prior to that, Oberton served as senior corporate controller for Immunogen, and as a senior audit manager for both Ernst Young and Arthur Andersen.

Jul 31, 2018

Rishi Kacker, Alexander Ford, Eric Evans, Lloyd Sanders

As part of Myriad Genetics' integration with recently acquired firm Counsyl, the company announced a number of personnel changes. Rishi Kacker, formerly Counsyl's senior VP of technology, will become Myriad's new chief technology officer. Alexander Ford, previously president of Myriad Genetic Laboratories, will be president of the company's women's health business unit, while Eric Evans, Counsyl's chief scientific officer, will now serve as the chief scientific officer of the women's health unit. Lastly, Lloyd Sanders, previously general manager of the oncology segment, will be president of Myriad's oncology business unit.

Jul 31, 2018

Markus Schunk

Definiens has announced that it appointed Markus Schunk as COO, effective Sept. 15, 2018. Prior to Definiens, Schunk was CEO and board chairman at Holtzbrinck Digital. 

Jul 31, 2018

Christian Henry

Pacific Biosciences has appointed Christian Henry to its board of directors. Henry has served in executive level positions at Illumina for more than 10 years, including most recently as executive VP and chief commercial officer. Prior to joining Illumina, he served as CFO of Tickets.com and VP of finance at Affymetrix. He is also on the board at Ginkgo Bioworks and WAVE Life Sciences.

Jul 31, 2018

Mark McDonough

Mark McDonough has been named chief business officer at diagnostics and bioinformatics firm Phosphorus. McDonough was previously president and CEO of CombiMatrix, now part of Invitae. He also held senior executive positions at Pathwork Dx and Laboratory Corporation of America. Phosphorus offers genetics testing in fertility, cardiology, lipidology, and other indications. It also offers the Elements software platform for labs to deploy the company's genetic tests on-premise as a local solution.

Jul 31, 2018

Roy Baynes

Natera has appointed Roy Baynes to its board of directors. Baynes is chief medical officer at Merck and senior vice president and head of global clinical development at Merck Research Laboratories. He has also held several roles at Gilead Sciences and Amgen and is a member of the American Society of Hematology, American Society of Clinical Oncology, and American Association for Cancer Research. Prior to joining industry, Baynes was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute.

Jul 30, 2018

Marianne Henderson

CloudLims announced today that it as appointed Marianne Henderson to its scientific advisory board. Henderson currently serves as senior advisor on biobanking at the National Cancer Institute's Center for Global Health, as well as senior advisor for Division Resources at the Division of Cancer Epidemiology, and Genetics (DCEG). Previously, Henderson served as DCEG's chief of office of division operations and analysis. 

Jul 26, 2018

James Lim

Syapse has hired James Lim as senior vice president of product development. In this role, he will head up development of Syapse's precision medicine platform, primarily for cancer patients. Lim is a former executive VP of product and engineering at Internet of Things technology developer Enlightened, a company acquired by Siemens in May. 

Jul 24, 2018

George Church, David Walt, Kevin Chen

Molecular diagnostics firm NuProbe Global has formed a scientific advisory board and appointed a new member to its board of directors. The firm has named George Church and David Walt as members of the scientific board. Church and Walt are currently professors of genetics and pathology, respectively, at Harvard Medical School. The firm has also appointed Kevin Chen, founding partner at Biotrack Capital, as a member of the board of directors. Chen has previously led investment in healthcare companies including Beijing Genomics Institute (BGI), Betta Pharma, and Yuwell Medical. 

Jul 24, 2018

Alex Dickinson, Robert Proulx

Alex Dickinson and Robert Proulx have joined the board of directors of Quantapore.

Dickinson is the founder and executive chairman of molecular diagnostics firm ChromaCode. Previously, he was a senior vice president at Illumina, and prior to that, the founder and CEO of molecular diagnostics firm Helixis, which Illumina acquired in 2010. Earlier, he was the founder and CEO of Luxtera, which provides silicon photonics products. Dickinson holds a PhD from the University of Adelaide in Australia and an MBA from Columbia University.

Proulx is executive chairman and CEO of Imagion Biosystems, a medical imaging company. Previously, he was the president of Silicon Biosystems, which was acquired by the Menarini Group. He also held executive positions at Nanogen, Gene Logic, Igen, and Packard Bioscience. Proulx holds MA and BA degrees from the State University of New York at Albany and an executive MBA from the Penn State Smeal College of Business.

Jul 24, 2018

Joseph Ecker

Zymo Research announced today that it has appointed Joseph Ecker to its scientific advisory board. Ecker currently serves as professor of plant molecular and cellular biology and director of the genomic analysis laboratory at the Salk Institute for Biological Studies. In addition, Ecker also serves as adjunct professor at the University of California, San Diego. 

Jul 23, 2018

Daniel Janse

Arbor Biotechnologies has appointed Daniel Janse as chief business officer. Janse most recently served as senior director of business development at Juno Therapeutics, and has held leadership positions at Johnson & Johnson, Inventages Venture Capital, Cell Therapy, McKinsey, and the Novartis Institutes for Biomedical Research. 
Jul 20, 2018

Jerry Williamson

NanoView Biosciences has appointed Jerry Williamson as CEO. Williamson succeeds David Freedman, who will remain with the firm as chief operating officer. Williamson has 30 years of experience in commercial operations, business development, and corporate management in the life science industry. He previously served as president and CEO of KEW, and as CEO and president of Metamark Genetics.

Jul 18, 2018

Feng Deng

Quantapore has announced that Feng Deng has joined the firm's board of directors in connection with the its latest financing round. Deng is the founder of Northern Light Venture Capital.

Jul 17, 2018

Laurence Klotz

MiR Scientific (formerly miR Diagnostics) has appointed Laurence Klotz as chief medical officer. Klotz currently serves as chairman of the World Urologic Oncology Federation. He has also been a member of the Institute of Medical Science and a graduate faculty member at the University of Toronto since 2005, as well as a professor of surgery at the University of Toronto since 2000.

Jul 13, 2018

David Karow

Human Longevity announced that its board has appointed David Karow interim CEO. Karow previously served as HLI's chief of radiogenomics. Prior to HLI, Karow spent twenty years in research, clinical practice, and training at the University of California, San Diego, the University of California, Los Angeles, and the University of Michigan.

Jul 13, 2018

Leena Das-Young

Guardant Health has appointed Leena Das-Young to serve as general manager of its LUNAR program. In her new role, Das-Young will oversee all work applying Guardant Health's technology and database of more than 70,000 clinical Guardant360 assay results, toward new applications in early-stage cancer, such as residual detection, recurrence monitoring, and early detection.

Prior to joining Guardant, Das-Young was vice president and head of the late phase strategy development group at Pfizer's oncology group, where she was responsible for a portfolio of oncology programs including Ibrance, Xalkori, Besponsa, Sutent, lorlatinib, and others. Prior to her roles in product development, she served in various commercial roles responsible for several successful launches at both Pfizer and Bayer.  She holds BS and Doctor of Pharmacy degrees from Purdue University.

Jul 13, 2018

Jinjie Hu

Laboratory for Advanced Medicine announced today that it has appointed Jinjie Hu as the firm's Chief Regulatory Officer. Hu currently serves as President and principal consultant at Axteria BioMed Consulting, and as senior consultant for Biologics Consulting Group. Hu has also served as World Health Organization advisor for its diagnostic pre-qualification program, as well as the International Network Committee chair of the FDA alumni association. 

Pages

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.